Downgrade Warning
S&P affirms negative outlook on India, says chances of downgrade remain
Ratings agency Standard & Poor's affirmed India's sovereign rating at "BBB-minus" with a "negative" outlook, reiterating there was a one-in-three chance of a ratings downgrade over the next 12 months, a statement said on Friday. Full Article
REUTERS SHOWCASE
Revitalising China
China president takes charge of sweeping economic reform plans - sources. Full Article
Buy, Sell or Hold?
Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade. Full Coverage
Reuters India Mobile
Get the latest news on the go. Visit Reuters India on your mobile device. Full Coverage
Cipla cuts prices of 3 cancer drugs by up to 64 pct
Track Markets: BSE Sectoral Indices
Track and analyse performance of all BSE sectoral indices and other global indices on a single page. Full Coverage
REUTERS - Drugmaker Cipla (CIPL.NS) cut prices of three cancer drugs between 50 percent and 64 percent with immediate effect, after it announced similar price cuts for three drugs early this year.
Lung cancer drug Erlocip would cost 9,900 rupees for 30 tablets instead of 27,000 rupees earlier, while breast cancer treatment Docetax would be priced 1,650 rupees instead of 3,300 rupees, Cipla said in a statement on Thursday.
Cipla last month won a case against Roche Holding (ROG.VX), which accused the Indian company of infringing patent on cancer drug Tarceva, which Cipla sells under the brand name Erlocip.
Capegard, another drug to treat metastatic colorectal and colon caner, would be priced 600 rupees for 10 tablets instead of 1,200 rupees, it said. (Reporting by Kaustubh Kulkarni and Manoj Dharra in Mumbai; Editing by Subhranshu Sahu)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Follow Reuters